口腔鳞癌合并三个及以上次要危险因素术后放疗联合化疗的倾向评分匹配分析
本研究探讨口腔鳞状细胞癌(OSCC)合并三个及以上次要危险因素患者术后放疗(RT)联合同步化疗(CCRT)的优势。经倾向评分匹配后每组各34例,中位随访86.4个月,CCRT组5年总生存率和无复发生存率均显著优于RT组。结论认为术后CCRT可提高此类患者的无复发生存和总生存。
要点
- 术后CCRT较单纯RT显著提高5年总生存(67.2% vs 35.3%,p=0.018)。
- 术后CCRT较单纯RT显著提高5年无复发生存(75.4% vs 42.6%,p<0.01)。
- 次要危险因素包括pT4、pN1、切缘≤4mm、低分化、神经侵犯、脉管侵犯、浸润深度≥11mm。
核心结论
- 对于具有三个及以上次要危险因素的口腔鳞癌患者,术后同步放化疗较单纯放疗可提高无复发生存和总生存。
研究设计与样本
- 回顾性队列研究,采用倾向评分匹配,匹配后RT组和CCRT组各34例。
- 次要危险因素包括pT4、pN1、切缘≤4mm、低分化、神经侵犯、脉管侵犯、肿瘤浸润深度≥11mm。
主要发现
- 存活患者中位随访86.4个月(范围47-189个月)。
- RT组与CCRT组5年总生存率分别为35.3%和67.2%(p=0.018)。
- RT组与CCRT组5年无复发生存率分别为42.6%和75.4%(p<0.01)。
关键数值与推荐
- 术后CCRT适用于具有三个及以上次要危险因素的口腔鳞癌患者。
临床怎么用
- 对具有三个及以上次要危险因素的口腔鳞癌术后患者,可考虑同步放化疗以改善生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To investigate the advantage of concurrent chemotherapy with postoperative radiotherapy (RT) of oral squamous cell carcinoma (OSCC) in patients with three or more minor risk factors. METHODS: Minor risk factors included pT4 disease, pN1 disease, margin ≤ 4 mm, poor differentiation, perineural invasion, vessel or lymphatic invasion, and tumor invasion depth ≥ 11 mm. Surgery was the primary treatment, followed by RT or concurrent chemoradiation (CCRT). After propensity score matching, 34 patients in each treatment group were selected for comparison. RESULTS: The median follow-up for living patients was 86.4 months (range: 47-189 months). The 5-year overall survival of the RT and CCRT groups was 35.3% and 67.2% (p = 0.018), respectively. The 5-year recurrence-free survival of the RT group and CCRT group was 42.6% and 75.4% (p < 0.01). CONCLUSION: Postoperative CCRT for patients with three or more minor risk factors increased recurrence-free and overall survival.
引用
- Fan KH, Chen YC, Lin CY, et al. Postoperative radiotherapy with or without concurrent chemotherapy for oral squamous cell carcinoma in patients with three or more minor risk factors: a propensity score matching analysis. Radiat Oncol. 2017. PMID: 29166942. doi:10.1186/s13014-017-0910-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。